Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 9 studies | 24% ± 10% | |
peripheral blood | 5 studies | 39% ± 17% | |
intestine | 5 studies | 25% ± 8% | |
liver | 5 studies | 25% ± 9% | |
eye | 4 studies | 22% ± 6% | |
brain | 4 studies | 31% ± 10% | |
placenta | 3 studies | 22% ± 4% | |
uterus | 3 studies | 31% ± 17% | |
breast | 3 studies | 19% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 6687.22 | 1445 / 1445 | 100% | 74.70 | 183 / 183 |
liver | 100% | 5022.88 | 226 / 226 | 100% | 68.20 | 406 / 406 |
ovary | 100% | 6579.56 | 180 / 180 | 100% | 78.46 | 430 / 430 |
pancreas | 100% | 5556.34 | 328 / 328 | 100% | 74.39 | 178 / 178 |
skin | 100% | 7494.43 | 1809 / 1809 | 100% | 114.26 | 472 / 472 |
thymus | 100% | 6423.86 | 653 / 653 | 100% | 89.48 | 605 / 605 |
uterus | 100% | 6590.36 | 170 / 170 | 100% | 91.47 | 459 / 459 |
brain | 100% | 7090.20 | 2638 / 2642 | 100% | 87.78 | 705 / 705 |
stomach | 100% | 5449.30 | 359 / 359 | 100% | 79.92 | 285 / 286 |
adrenal gland | 100% | 8213.17 | 258 / 258 | 100% | 80.10 | 229 / 230 |
kidney | 100% | 5683.44 | 89 / 89 | 99% | 56.42 | 896 / 901 |
intestine | 100% | 7463.93 | 966 / 966 | 99% | 91.11 | 524 / 527 |
prostate | 100% | 8079.51 | 245 / 245 | 99% | 101.41 | 498 / 502 |
lung | 100% | 5708.56 | 576 / 578 | 99% | 68.05 | 1146 / 1155 |
breast | 100% | 5718.78 | 459 / 459 | 99% | 66.48 | 1105 / 1118 |
bladder | 100% | 6126.05 | 21 / 21 | 99% | 85.80 | 498 / 504 |
adipose | 100% | 5818.78 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 180.39 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 136.94 | 29 / 29 |
muscle | 100% | 10598.91 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 7423.23 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 95.99 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 77.22 | 1 / 1 |
peripheral blood | 100% | 8546.89 | 928 / 929 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 4578.21 | 1333 / 1335 | 0% | 0 | 0 / 0 |
heart | 100% | 6158.84 | 859 / 861 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_2000641 | Biological process | regulation of early endosome to late endosome transport |
GO_0038133 | Biological process | ERBB2-ERBB3 signaling pathway |
GO_0050772 | Biological process | positive regulation of axonogenesis |
GO_0042552 | Biological process | myelination |
GO_0000165 | Biological process | MAPK cascade |
GO_0007507 | Biological process | heart development |
GO_0048009 | Biological process | insulin-like growth factor receptor signaling pathway |
GO_0090170 | Biological process | regulation of Golgi inheritance |
GO_0010628 | Biological process | positive regulation of gene expression |
GO_2000147 | Biological process | positive regulation of cell motility |
GO_0030878 | Biological process | thyroid gland development |
GO_0032872 | Biological process | regulation of stress-activated MAPK cascade |
GO_0048679 | Biological process | regulation of axon regeneration |
GO_0060440 | Biological process | trachea formation |
GO_0070371 | Biological process | ERK1 and ERK2 cascade |
GO_0014044 | Biological process | Schwann cell development |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_0060324 | Biological process | face development |
GO_0048538 | Biological process | thymus development |
GO_0036289 | Biological process | peptidyl-serine autophosphorylation |
GO_0060502 | Biological process | epithelial cell proliferation involved in lung morphogenesis |
GO_0071902 | Biological process | positive regulation of protein serine/threonine kinase activity |
GO_0005778 | Cellular component | peroxisomal membrane |
GO_0005576 | Cellular component | extracellular region |
GO_0005874 | Cellular component | microtubule |
GO_0048471 | Cellular component | perinuclear region of cytoplasm |
GO_0005739 | Cellular component | mitochondrion |
GO_0005769 | Cellular component | early endosome |
GO_0009898 | Cellular component | cytoplasmic side of plasma membrane |
GO_0005794 | Cellular component | Golgi apparatus |
GO_0005925 | Cellular component | focal adhesion |
GO_0005911 | Cellular component | cell-cell junction |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005829 | Cellular component | cytosol |
GO_0005770 | Cellular component | late endosome |
GO_0005634 | Cellular component | nucleus |
GO_0004712 | Molecular function | protein serine/threonine/tyrosine kinase activity |
GO_0106310 | Molecular function | protein serine kinase activity |
GO_0005078 | Molecular function | MAP-kinase scaffold activity |
GO_0004713 | Molecular function | protein tyrosine kinase activity |
GO_0004708 | Molecular function | MAP kinase kinase activity |
GO_0004674 | Molecular function | protein serine/threonine kinase activity |
GO_0043539 | Molecular function | protein serine/threonine kinase activator activity |
GO_0030165 | Molecular function | PDZ domain binding |
GO_0097110 | Molecular function | scaffold protein binding |
GO_0046872 | Molecular function | metal ion binding |
GO_0005524 | Molecular function | ATP binding |
GO_0005515 | Molecular function | protein binding |
Gene name | MAP2K2 |
Protein name | mitogen-activated protein kinase kinase (EC 2.7.12.2) Dual specificity mitogen-activated protein kinase kinase 2 (MAP kinase kinase 2) (MAPKK 2) (EC 2.7.12.2) (ERK activator kinase 2) (MAPK/ERK kinase 2) (MEK 2) |
Synonyms | MKK2 MEK2 hCG_23544 PRKMK2 |
Description | FUNCTION: Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates the ERK1 and ERK2 MAP kinases (By similarity). Activates BRAF in a KSR1 or KSR2-dependent manner; by binding to KSR1 or KSR2 releases the inhibitory intramolecular interaction between KSR1 or KSR2 protein kinase and N-terminal domains which promotes KSR1 or KSR2-BRAF dimerization and BRAF activation . . |
Accessions | P36507 M0R1B6 B3KS97 ENST00000599021.1 ENST00000262948.10 |